Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence and BioWorld by Clarivate, today published a new e-book, Pulsed field ablation: stunning growth shocks the atrial ...

New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment LONDON, Feb. 4, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

The atrial fibrillation (AF) device market is experiencing rapid growth, fueled by the rising prevalence of atrial fibrillation, increasing awareness of early diagnosis, and advancements in medical ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ...

PFA targets abnormal cardiac tissue to reduce damage to surrounding areas. South Korea’s Asan Medical Centre (AMC) has ...

"US pulsed field ablation market revenue exceeds $500m in 2024" was originally created and published by Medical Device ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

Unlike conventional radiofrequency ablation and cryoablation for atrial fibrillation, PFA relies on microsecond-scale, high-voltage electrical fields to induce cardiac cell death to isolate the ...

Amy Paterson, Medical Analyst at GlobalData states, “Medtronic’s Sphere-9 launched at a lower price than Boston Scientific’s ...